{"prompt": "['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', 'the policy that would apply to patients with similar therapy outside the trial). This may', 'include assessment of vaccination status, anamnesis, physical examination and', 'potentially antigen and/or PCR testing.', '28. Patient committed to an institution by virtue of an order issued either by the judicial or the', 'administrative authorities.', '29. Limited legal capacity.', '5.1.3 Lifestyle Considerations', '5.1.3.1 Meals and Dietary Restrictions', 'Participants should maintain a normal diet unless modifications are required to manage an AE', 'such as diarrhea, nausea or vomiting.', '5.1.3.2 Contraception', 'FOLFOX and FOLFOXIRI-based chemotherapy may have adverse effects on a fetus in utero.', 'Refer to Appendix 3 for approved methods of contraception.', 'For this study, male participants will be considered to be of non-reproductive potential if they', 'have azoospermia (whether due to having had a vasectomy or due to an underlying medical', 'condition).', '5.1.4 Pregnancy', 'If a participant inadvertently becomes pregnant during trial intervention, the participant will be', 'immediately discontinued from trial intervention(s). The site will contact the participant at least', \"monthly and document the participant's status until the pregnancy has been completed or\", 'terminated. The outcome of the pregnancy will be reported to the Sponsor or designee if the', 'outcome is a serious adverse experience (e.g., death, abortion, congenital anomaly, or other', 'disabling or life-threatening complication to the mother or new-born). The study Investigator', 'will make every effort to obtain permission to follow the outcome of the pregnancy and report', 'the condition of the foetus or new-born to the Sponsor or designee. If a male participant', 'impregnates his female partner, the study personnel at the site must be informed immediately', 'and the pregnancy must be reported to the Sponsor or designee and followed as described in', 'Section 6.2.2.5.', '5.2 Trial Intervention(s)', 'The study drug intervention(s) to be used in Arm A of this trial are mFOLFOX-6 or', 'mFOLFOXIRI. A guidance is outlined in Table 2, however, at the discretion of the investigator,', 'site specific modifications are permitted, e.g. additional 5-FU bolus, parallel leucovorin and', 'oxaliplatin administration or variation of the infusion rates.', 'Confidential', 'Page 35 of 79']['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', 'Table 2: Trial Medication (guidance for administration)', 'Duration of', 'Route of', 'Day(s) of', 'Drug', 'Dose/Potency', 'administration*', 'Administration', 'application', 'mFOLFOX-6', 'regimen:', 'Oxaliplatin', '85 mg/m\u00b2', '2h', 'IV Infusion', 'd1 of each', 'Leucovorin', '400 mg/m\u00b2', '1-2h', 'IV Infusion', 'chemotherapy', '5-FU*', '400 mg/m\u00b2 bolus**', '2-5 min', 'IV Infusion', 'cycle', '2400 mg/m\u00b2', '46h', 'IV Infusion', 'mFOLFOXIRI', 'regimen:', 'Oxaliplatin', '85 mg/m\u00b2', '2h', 'IV Infusion', 'd1 of each', 'Irinotecan', '150 mg/m\u00b2', '90min', 'IV Infusion', 'chemotherapy', 'Leucovorin', '400 mg/m\u00b2', '1-2h', 'IV Infusion', 'cycle', '5-FU*', '2400 mg/m\u00b2', '46h', 'IV Infusion', '* in DPD mutation carriers with a CPIC activity score of 1.0-1.5, 5-FU Dosage should be reduced by 50%.', '**', 'additional 400mg/m\u00b2 bolus is permitted but not mandatory.', 'infusion rates of chemotherapeutical components represent recommendations but might be modified according', 'to local standards', 'The guidance given in this protocol section does not replace the careful reading of the', 'summary of product characteristics (SmPC) for each component!', '5.2.1 Timing of Dose Administration', 'Trial interventions should be administered on day 1 of each cycle after all', 'procedures/assessments have been completed as detailed on the Schedule of Trial Activities', '(Section 2.3). From the second cycle onwards, the chemotherapy may be administered up to', '5 days after the scheduled day 1 of the respective cycles, due to administrative reasons with', 'a minimum time span of 14 days between the cycles.', 'All trial interventions will be administered on an outpatient basis.', '5.2.2 Prerequisites for Application of Trial Intervention', 'The following rule must be followed, as it describes an exclusion criterion:', 'The patient is not eligible to participate in this study if', '> 12 weeks (> 6 cycles) of FOLFOXIRI or FOLFOX (q14d cycles)', 'or', '> 12 weeks (> 4 cycles) of CAPOX or XELOX (q21d cycles)', 'or', 'a combination of the above therapies accumulating in > 12 weeks of therapy', 'was received as pre-treatment.', 'Confidential', 'Page 36 of 79']\n\n###\n\n", "completion": "END"}